학술논문
A Comprehensive Review of Cancer Drug-Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies.
Document Type
Academic Journal
Author
Costanzo V; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.; Ratre YK; Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India.; Andretta E; Department of Veterinary Medicine and Animal Productions, University of Naples 'Federico II', Naples, Italy.; Acharya R; Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India.; Bhaskar LVKS; Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India.; Verma HK; Department of Immunopathology, Institute of Lungs Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Neuherberg, 85764, Munich, Germany. henu.verma@yahoo.com.
Source
Publisher: Current Science, Inc Country of Publication: United States NLM ID: 100900946 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6277 (Electronic) Linking ISSN: 15346277 NLM ISO Abbreviation: Curr Treat Options Oncol Subsets: MEDLINE
Subject
Language
English
Abstract
Opinion Statement: Cardiotoxicity has emerged as a serious outcome catalyzed by various therapeutic targets in the field of cancer treatment, which includes chemotherapy, radiation, and targeted therapies. The growing significance of cancer drug-induced cardiotoxicity (CDIC) and radiation-induced cardiotoxicity (CRIC) necessitates immediate attention. This article intricately unveils how cancer treatments cause cardiotoxicity, which is exacerbated by patient-specific risks. In particular, drugs like anthracyclines, alkylating agents, and tyrosine kinase inhibitors pose a risk, along with factors such as hypertension and diabetes. Mechanistic insights into oxidative stress and topoisomerase-II-B inhibition are crucial, while cardiac biomarkers show early damage. Timely intervention and prompt treatment, especially with specific agents like dexrazoxane and beta-blockers, are pivotal in the proactive management of CDIC.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)